Southern Research Institute Signs Agreement with Absorption Systems to Provide Toxicology Services
News Feb 02, 2007
Southern Research Institute and Absorption Systems, LP announced that they have signed an agreement that will allow the two organizations to collaborate in providing contract research services in the areas of toxicology and bioanalytical services to biotechnology and pharmaceutical clients.
According to the agreement, Southern Research and Absorption Systems will work jointly to offer expanded preclinical development services to their clients for new compounds about to enter clinical development, and will conduct collaborative business development, co-marketing and scientific publication projects.
"We are very pleased to be working with Southern Research. This collaboration will allow us to combine Southern Research's world-renowned toxicology services and drug development expertise with Absorption System's expertise in bioanalytical services, metabolite profiling, and preclinical formulation development in order provide the highest quality services to the pharmaceutical and biotech industry," said Patrick Dentinger, president and CEO of Absorption Systems.
"The relationship with Absorption Systems will allow both companies to leverage our individual strengths for the benefit of our pharmaceutical and biotech clients by generating better and faster study data as new drugs move forward," said Tina Rogers, Ph.D., vice president of the Drug Development Division at Southern Research.
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE